title: Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.
abstract: The neuroprotective effects of granulocyte colony-stimulating factor (G-CSF) were reported in several neurological disease models, including Parkinson's disease (PD). In the present study, we investigated the therapeutic effect of G-CSF after the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD was established. G-CSF was subcutaneously administered into C57BL/6 mice that had undergone systemic MPTP injections. We found that G-CSF treatment markedly increased the number of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the G-CSF-treated group. Consistent with this finding, we found a significant increase in dopamine release under high K(+) stimulation in the striatum of the G-CSF-treated animals compared to the MPTP-exposed mice. Finally, we observed a persistent recovery of locomotor function in the G-CSF-treated animals. These results suggest the potential therapeutic value of G-CSF in treating PD. However, our bromodeoxyuridine labeling experiment failed to identify any newly generated dopaminergic neurons in SNpc. This might indicate an indirect effect of G-CSF on cell proliferation. The underlying mechanism of G-CSF is under further investigation.
authors.affiliation: Department of Basic Science, Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: McCollum
authors.forename: Zhiyuan
authors.initials: Z
authors.lastname: Ma
authors.forename: Eric
authors.initials: E
authors.lastname: Cohen
authors.forename: Rebecca
authors.initials: R
authors.lastname: Leon
authors.forename: Rui
authors.initials: R
authors.lastname: Tao
authors.forename: Jang-Yen
authors.initials: JY
authors.lastname: Wu
authors.forename: Dipnarine
authors.initials: D
authors.lastname: Maharaj
authors.forename: Jianning
authors.initials: J
authors.lastname: Wei
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects* / Q000473:pathology / Q000502:physiology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D020267:MPTP Poisoning / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017551:Microdialysis; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects* / Q000473:pathology / Q000502:physiology*
chemical_list: D015259:Dopamine Agents; D016179:Granulocyte Colony-Stimulating Factor; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine
references.citation: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7925-30
references.pmid: 12792021
references.citation: Nat Protoc. 2007;2(1):141-51
references.pmid: 17401348
references.citation: Cell Cycle. 2005 Dec;4(12):1753-7
references.pmid: 16258290
references.citation: J Neurochem. 2006 Nov;99(3):861-7
references.pmid: 17076657
references.citation: Ann Neurol. 2005 Jul;58(1):31-40
references.pmid: 15912513
references.citation: Neurobiol Dis. 2003 Nov;14(2):218-28
references.pmid: 14572444
references.citation: Front Biosci. 2007 May 01;12:2869-75
references.pmid: 17485265
references.citation: Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14686-91
references.pmid: 11121069
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10177-82
references.pmid: 15210991
references.citation: Cell. 2008 Feb 22;132(4):645-60
references.pmid: 18295581
references.citation: Dev Neurosci. 2000;22(1-2):56-67
references.pmid: 10657698
references.citation: Behav Brain Res. 2001 Nov 1;125(1-2):109-25
references.pmid: 11682102
references.citation: J Neurophysiol. 2001 Mar;85(3):1270-4
references.pmid: 11247995
references.citation: Nat Neurosci. 2004 Jul;7(7):726-35
references.pmid: 15195095
references.citation: J Neurochem. 2006 May;97(3):675-86
references.pmid: 16573658
references.citation: Brain Res. 2006 Aug 23;1106(1):30-39
references.pmid: 16843444
references.citation: J Neurosci. 2002 Aug 1;22(15):6639-49
references.pmid: 12151543
references.citation: J Clin Invest. 2005 Aug;115(8):2083-98
references.pmid: 16007267
references.citation: Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5
references.pmid: 12666094
references.citation: J Cereb Blood Flow Metab. 2005 Apr;25(4):431-9
references.pmid: 15660101
references.citation: Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):57-65
references.pmid: 11718836
references.citation: J Neurosci. 2001 Sep 1;21(17):6718-31
references.pmid: 11517261
references.citation: Nature. 2000 Oct 26;407(6807):963-70
references.pmid: 11069169
references.citation: Stem Cells. 2006 May;24(5):1280-7
references.pmid: 16424396
references.citation: J Cereb Blood Flow Metab. 2006 Mar;26(3):402-13
references.pmid: 16049425
references.citation: Annu Rev Neurosci. 2005;28:223-50
references.pmid: 16022595
references.citation: Brain Res. 2008 Feb 15;1194:130-7
references.pmid: 18166168
references.citation: Neurobiol Aging. 2007 Aug;28(8):1258-69
references.pmid: 16839644
references.citation: Discov Med. 2006 Aug;6(34):144-7
references.pmid: 17234134
references.citation: Stroke. 2003 Mar;34(3):745-51
references.pmid: 12624302
references.citation: Blood. 1991 Dec 1;78(11):2791-808
references.pmid: 1720034